GlaxoSmithkline - CHMP recommends expansion of Trelegy COPD label
Posted: September 21st, 2018, 5:02 pm
Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe
https://www.investegate.co.uk/glaxosmit ... 30035747B/
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol 'FF/UMEC/VI') in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD.
https://www.investegate.co.uk/glaxosmit ... 30035747B/